We used gene expression profiling to investigate whether the molecular effects induced by estrogens of different provenance are intrinsically similar. In this article we show that the physiologic estrogen 17β-estradiol, the phytoestrogen genistein, and the synthetic estrogen diethylstilbestrol alter the expression of the same 179 genes in the intact immature mouse uterus under conditions where each chemical has produced an equivalent gravimetric and histologic uterotrophic effect, using the standard 3-day assay protocol. Data are also presented indicating the limitations associated with comparison of gene expression profiles for different chemicals at times before the uterotrophic effects are fully realized. We conclude that the case has yet to be made for regarding synthetic estrogens as presenting a unique human hazard compared with phytoestrogens and physiologic estrogens.
The question of whether phytoestrogens and synthetic estrogens are toxicologically similar, or intrinsically different, presents a challenge to all involved in human hazard and risk assessments. Although there is a general concern that exposure to nanogram or microgram amounts of environmental estrogens may be associated with adverse health effects, in the public mind there is a widespread belief that foods and dietary supplements containing milligram quantities of phytoestrogens confer only health benefits. An implicit distinction therefore seems to have been drawn between synthetic and plant-derived estrogens-a belief sustained in the public mind by the assumption that natural is good and synthetic is bad-but an untested and potentially misleading notion for those involved with sciencebased human hazard/risk assessments.
Phytoestrogens and synthetic estrogens are generally considered separately in the literature. For example, Howdeshell et al. (1999) suggested a possible association between the advance in first estrus observed in mice exposed in utero to 2.4 µg/kg of the synthetic environmental estrogen bisphenol A and reports of an increased incidence of hypospadias in boys (Paulozzi et al. 1997 ) and the earlier sexual maturation of girls (Herman-Giddens et al. 1997 )-the implication being that synthetic estrogens present a greater hazard than the much higher levels of phytoestrogens being consumed by those same children. In contrast, there are reports of an increased incidence of hypospadias in boys born to vegetarians (North and Golding 2000) , of alterations in the menstrual cycle (Cassidy et al. 1994) , and of reduced breast cancer incidences (Messina 1999) among women eating diets rich in phytoestrogens. Support for these epidemiologic observations comes from experimental studies indicating that advances in sexual development in rodents can be induced by their exposure to phytoestrogens (Casanova et al. 1999; Cassidy and Faughnan 2000; Safe et al. 2002) . In contrast to these separate lines of inquiry, Newbold and colleagues have evaluated potential similarities between natural and synthetic estrogens. In seminal studies, they demonstrated that neonatal exposure of female mice to equipotent uterotrophic doses of the phytoestrogen genistein (GEN; Figure 1 ) or the synthetic estrogen diethylstilbestrol (DES) leads to an identical incidence of uterine adenomas at 18 months of age (Newbold et al. 2001) . However, in attempting to draw parallels, or distinctions, between phytoestrogens and synthetic estrogens, it is imperative to consider growing awareness of the complexity of estrogen signaling pathway and the pleuripotential biologic activities of most organic chemicalsirrespective of their origin.
Estrogen signaling in mammalian cells is primarily mediated at the molecular level by two members of the nuclear receptor superfamily-estrogen receptors alpha (ER-α) and beta (ER-β). Ligand-activated ER-α and ER-β function as transcription factors, in conjunction with numerous coregulatory proteins, in order to activate or repress the transcription of ER-responsive genes (Hall et al. 2001; Moggs and Orphanides 2001) . There is considerable variation in the binding affinity of ER-α and ER-β among different estrogens (Kuiper et al. 1998 ). In the case of the chemicals studied here, the physiologic estrogen 17β-estradiol (E 2 ) and DES bind with a similar affinity to ER-α and ER-β, whereas GEN binds with approximately 20-fold higher affinity to ER-β than to ER-α (Kuiper et al. 1998) . Concerning nonhormonal properties of the test chemicals (most of which have only be defined in vitro), GEN inhibits a range of enzymes, including tyrosine kinases (Akiyama et al. 1987) , nitric oxide synthase (Duarte et al. 1997) , and topoisomerase II (Okura et al. 1988) , and also decreases calcium-channel activity (Potier and Rovira 1999) , lipid peroxidation (Arora et al. 1998) , and diacylglycerol synthesis (Dean et al. 1989) . Likewise, DES is reported to induce aneuploidy in mammalian cells (Aardema et al. 1998) and to bind to rat liver DNA (Williams et al. 1993 ). More recently, some phytoestrogens were reported to inhibit the aromatase-mediated conversion of testosterone to E 2 in vitro (Almstrup et al. 2002) , and equol, the major circulating estrogenic metabolite associated with the dietary ingestion of phytoestrogens, is reported to selectively sequester dihydrotestosterone and thereby to act as a functional antiandrogen in vivo (Lund et al. 2004) .
In order to advance understanding in this area, we decided to compare the genes expressed in the immature mouse uterus when it had grown in response to treatment with the estrogens E 2 , DES, and GEN. The immature mouse uterus was selected for our analysis because it is a major estrogen-responsive organ and forms the basis for a reference assay of estrogenic activity (Owens and Ashby 2002) , including carcinogenesis (Newbold et al. 2001 ). Furthermore, it expresses both ER-α and ER-β (Weihua et al. 2000) and the androgen receptor (Frasor et al. 2003) . We initially conducted a global analysis of gene expression in the mouse uterus at 1, 2, 4, 8, 24, 48, and 72 hr after exposure to a single high dose of either GEN (250 mg/kg) or E 2 (400 µg/kg). These single high doses yielded a sustained uterotrophic response over 72 hr ( Figure 2A ) and were selected to avoid the complex transcriptional program that may result from the standard uterotrophic assay exposure regime in which each test compound is dosed by repeated administration on 3 consecutive days (Odum et al. 1997 (GEO 2004) . These data were analyzed using unsupervised hierarchical clustering and yielded temporal relationships between the expression profiles of 3,450 genes that were either up-or down-regulated (> 1.5-fold) by E 2 and/or GEN ( Figure 2B ). Each chemical induced a similar, multistage transcriptional response ( Figure 2B ), although it is noteworthy that we observed variations in the magnitude and timing of both early (e.g., c-fos) and late (e.g., lactotransferrin) ER-responsive genes during the uterotrophic responses induced by E 2 and GEN ( Figure 2C) .
A detailed description of the molecular functions of the genes affected, together with their association with physiologic changes during uterine growth, has been reported (Orphanides et al. 2003) and will be described VOLUME 112 | NUMBER 11 | August 2004 • Environmental Health Perspectives in more detail in a future publication (Moggs et al., unpublished data) . These observations suggest that GEN does not induce "off-target" ER-independent transcriptional responses, that is, those associated with the properties of GEN other than estrogenicity. Furthermore, there was no evidence for the topoisomerase II-inhibiting properties of GEN in the bone marrow of the present mice despite demonstration of the sensitivity of that tissue to the potent micronucleus-inducing activity of the topoisomerase II inhibitor etoposide (data not shown). Together, these data led us to question whether a synthetic estrogen such as DES would also induce similar transcriptional responses in the immature mouse uterus.
In order to avoid temporal vagaries in gene expression (e.g., Figure 2C ), we decided to anchor our transcript profiling data to the phenotype of the grown uterus by employing equipotent uterotrophic doses of E 2 , GEN, and DES. We compared the global gene expression profiles in the uteri of intact immature mice stimulated with three daily low doses of either GEN, DES, or E 2 , with an exposure regimen the same as that used in a standard 3-day uterotrophic assay (Odum et al. 1997) . The route of administration and the doses of GEN and DES used were as described by Newbold et al. (2001) in their equivalent-outcome carcinogenicity bioassays of these two chemicals. Three independent replicates of four groups of sexually immature mice (Alpk:APfCD-1; 19/20 days of age; maintained on RM1 diet) received three daily subcutaneous injections of GEN (50 mg/kg), E 2 (2.5 µg/kg), or DES (2 µg/kg). Control animals received the vehicle, AO (5 mL/kg). These doses elicited similar uterotrophic responses (72 hr after the initial dose; Figure 3A , Table 1 ) and identical histologic changes in the uteri of the treated animals (Table 1) . Uterine RNA was isolated and pooled for each of the 12 groups and analyzed for changes in gene expression levels using the same Affymetrix microarray of 12,488 mouse genes. The data were analyzed using two independent statistical methods. First, unsupervised hierarchical clustering defined the global relationships (Euclidean distances) between the 12 gene expression profiles ( Figure 3B ). The three control groups clustered under one node, whereas the chemical treatment groups formed a separate node of compoundindependent clusters, indicating equal similarity within and between the transcriptional responses induced by the three estrogens ( Figure 3B) . One-way analysis of variance (ANOVA), with Bonferroni (Holm 1979) correction (familywise error rate < 0.05) to minimize false positives, identified 179 genes where expression levels were altered by one or more chemical treatments ( Figure 3C ). Remarkably, Tukey post hoc testing revealed that all of these genes were affected in all nine compound treatment groups. Table 2 highlights the high degree of similarity between the transcriptional responses to each of the three estrogens. These include established estrogen-responsive genes such as lactotransferrin, complement component 3, c-fos, small proline-rich protein 2A, and keratoepithelin (Hewitt et al. 2003; Naciff et al. 2003) 
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Up-regulated genes
Solute carrier family 9a3r1 U74079 1.8 ± 0.01 2.0 ± 0.1 2.0 ± 0.2 Keratin complex 2-8 X15662 2.6 ± 0.2 3.1 ± 0.2 3.1 ± 0.3 Laminin beta 3 U43298 4.3 ± 0.1 5.5 ± 1.1 5.3 ± 0.7 Claudin 7 AF087825 4.5 ± 0.5 6.5 ± 1.0 5.8 ± 0.6 bHLH-Zip transcription factor U49507 2.6 ± 0.3 3.1 ± 0.3 2.9 ± 0.1 RIKEN cDNA 1200008D14 AW208938 3.0 ± 0.3 3.5 ± 0.1 3.3 ± 0.3 Basic HLH-domain containing, Y07836
5.9 ± 1.0 6.6 ± 0.9 6.6 ± 0.8 class B2 RIKEN cDNA 9930104H07 AW122310 3.0 ± 0.3 3.2 ± 0.4 3.3 ± 0.1 Fucosyltransferase 2 AF064792 27.5 ± 1.2 34.6 ± 8.5 36.7 ± 5.5 Deleted in polyposis 1 U28168 1.8 ± 0.1 2.0 ± 0.02 2.0 ± 0.1 Microsomal glutathione AI843448 2.9 ± 0.2 3.3 ± 0.6 3.3 ± 0.1 S-transferase 3 Tumor-associated Ca signal Y08830 4.0 ± 0.3 4.6 ± 0.9 4.6 ± 0.3 transducer 2 Calpain 5 Y10656 5.5 ± 0.4 6.3 ± 1.0 6.6 ± 0.6 Mitochondrial creatine kinase Z13969 9.7 ± 1.1 12.2 ± 2.1 13.1 ± 1.8 ATPase 6v1a1 AW123765 2.0 ± 0.1 2.1 ± 0.2 2.1 ± 0.2 Tumor-associated Ca signal AI563854 8.0 ± 0.4 9.2 ± 1.0 8.5 ± 0.4 transducer 2 Lymphocyte antigen 6 complex, X04653
7.8 ± 0.9 8.8 ± 0.3 8.5 ± 0.4 locus A Chloride channel calcium-AV373378 26.4 ± 3.4 26.7 ± 1.0 26.2 ± 3.9 activated 3 Small proline-rich protein 2I AJ005567 23.9 ± 1.5 24.7 ± 1.3 23.6 ± 1.6
Oncoprotein induced transcript 1 AA615075 19.0 ± 3.1 20.0 ± 1.2 18.9 ± 2.5 Small proline-rich protein 2F AJ005564 59.8 ± 8.4 65.8 ± 1.1 60.6 ± 2.6 Small proline-rich protein 2E AJ005563 12.0 ± 1.0 12.9 ± 0.8 12.1 ± 0.9 Mucin 1 M84683 8.3 ± 0.6 8.6 ± 0.3 8.5 ± 0.5 Lipoocalin 2 X81627 150.3 ± 15.0 175.7 ± 10.5 162.8 ± 6.5 RIKEN cDNA 2210409B01 AF109906 3.5 ± 0.6 4.0 ± 0.3 3.8 ± 0.8 Interferon-activated gene 202A M31418 7.9 ± 1.0 9.8 ± 2.5 8.8 ± 0.7 Nuclear ankyrin-repeat protein AA614971 3.7 ± 0.6 4.3 ± 0.7 4.1 ± 0.9 RIKEN cDNA 5730469M10 AI850090 22.0 ± 5.8 30.5 ± 9.1 27.0 ± 6.5 RIKEN cDNA 1110034C02 AI837104 1.5 ± 0.1 1.6 ± 0.1 1.6 ± 0.03 IMAGE cDNA 4988271 AV373294 8.0 ± 2.5 10.6 ± 1.6 9.2 ± 1.1 RIKEN cDNA 5730493B19 AW122413 12.7 ± 0.3 19.0 ± 4.1 15.7 ± 0.9 Peptidoglycan recognition AV092014 13.4 ± 1.5 18.3 ± 3.0 14.5 ± 2.1 protein Inhibin beta-B X69620 13.6 ± 3.1 19.4 ± 4.7 16.0 ± 1.4 CEA-related cell adhesion AF101164 11.9 ± 1.6 17.8 ± 5.3 14.2 ± 1.7 molecule 2 Keratin complex 1-19 M36120 4.4 ± 0.4 5.5 ± 1.1 4.8 ± 0.5 CEA-related cell adhesion M77196 15.9 ± 2.4 23.9 ± 5.9 19.0 ± 3.8 molecule 1 SRC family-associated AB014485 2.7 ± 0.04 3.2 ± 0.4 2.9 ± 0.3 phosphoprotein 2 Peptidoglycan recognition AF076482 7.7 ± 1.9 10.4 ± 2.7 9.0 ± 2.0 protein CEA-related cell adhesion M77196 19.5 ± 3.9 30.4 ± 8.8 22.2 ± 2.7 molecule 1 previously been associated with estrogenicity (Table 2) .
Although these three estrogens can alter the expression of some genes with different magnitudes [e.g., peptidyl arginine deiminase II is up-regulated to a lesser extent by E 2 (1.86-fold ± 0.27) relative to GEN (9.11-fold ± 0.33) and DES (5.15-fold ± 1.53); Table 2 ], the present data show that the same genes are affected during equivalent uterotrophic responses. Previous studies have revealed both similarities and differences between transcriptional responses induced at a single time point after exposure to E 2 and DES in the uteri of immature ovariectomized mice (Watanabe et al. 2003 ) and after exposure to either GEN, bisphenol A, or 17α-ethynyl estradiol in the reproductive tract of intact adult rats (Naciff et al. 2002) . We suggest that these reported differences most probably arise from dose-dependent variations in the magnitude and kinetics of gene expression ( Figure 2C ), rather than from the operation of distinct mechanisms of estrogenic action.
Our data indicate that estrogens of differing provenance may have in common the potential for both beneficial and adverse health effects. This highlights the need for an holistic approach to hazard assessment wherein preconceptions are replaced by an objective assessment of the likely perturbations of physiologic functions caused by combined exposures to physiologic, synthetic, and plantderived estrogens. This need is reinforced by data showing that plasma concentrations of isoflavones in infants fed soy formula are approximately 200 times higher than for those fed human milk (Setchell et al. 1997) 
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CEA-related cell adhesion X67279 6.4 ± 0.7 8.4 ± 1.1 7.1 ± 1.1 molecule 1 Spermidine N1-acetyl L10244 8.3 ± 0.9 11.2 ± 0.8 9.3 ± 0.6 transferase RIKEN cDNA 0610007O07 AI851762 2.7 ± 0.1 3.0 ± 0.3 2.8 ± 0.1 Arginase 1 U51805 79.4 ± 9.8 131.9 ± 20.0 99.6 ± 14.5 Acetyl-coenzyme A synthetase 2 AW125884 2.2 ± 0.2 2.0 ± 0.1 2.2 ± 0.2 v-erb-b2 homolog 3 AI006228 3.4 ± 0.4 3.1 ± 0.6 3.4 ± 0.4 Phospholipase D3 AF026124 2.6 ± 0.2 2.4 ± 0.2 2.6 ± 0.2 RIKEN cDNA 0610031J06 AW122935 1.9 ± 0.1 1.8 ± 0.1 1.8 ± 0.1 Complement component 1q X58861 2.1 ± 0.1 2.0 ± 0.1 2.0 ± 0.2 Scotin AW123754 2.0 ± 0.1 2.0 ± 0.2 2.0 ± 0.2 CD24a antigen M58661 3.2 ± 0.1 3.1 ± 0.1 3.3 ± 0.3 Argininosuccinate synthetase 1 M31690 2.7 ± 0.3 2.7 ± 0.3 2.8 ± 0.4 ATPase 6v1a1 U13837 2.1 ± 0.1 2.1 ± 0.2 2.2 ± 0.2 Gelsolin-like actin-capping X54511 3.6 ± 0.5 3.7 ± 0.5 3.7 ± 0.2 protein Golgi phosphoprotein 2 AW125446 4.5 ± 0.5 4.6 ± 0.5 4.7 ± 0.1 Aldolase 1A Y00516 2.3 ± 0.2 2.3 ± 0.1 2.4 ± 0.1 Cathepsin L X06086 6.4 ± 0.8 6.3 ± 1.1 6.9 ± 0.4 CD14 antigen X13333 3.0 ± 0.1 2.8 ± 0.1 3.1 ± 0.2 Decay accelerating factor 2 L41365 4.0 ± 0.1 3.8 ± 0.8 3.8 ± 0.2 Actin-related protein AW212775 2.1 ± 0.2 2.1 ± 0.1 2.1 ± 0.2 2/3 complex 1B Protective protein for J05261 2.0 ± 0.1 2.0± 0.1 2.0 ± 0.1 β-galactosidase Elastase 1 M27347 2.7 ± 0.1 2.5 ± 0.2 2.6 ± 0.1 Connexin 26 M81445 10.6 ± 1.0 9.8 ± 0.5 10.4 ± 0.8 Ceruloplasmin U49430 15.1 ± 2.8 15.0 ± 5.5 14.5 ± 2.1 Cathepsin H U06119 3.0 ± 0.2 3.0 ± 0.3 3.0 ± 0.3 Basigin Y16258 1.6 ± 0.1 1.5 ± 0.1 1.7 ± 0.1 Peptidylprolyl isomerase X67809 2.2 ± 0.2 2.2 ± 0.1 2.4 ± 0.3 C-associated Glutathione reductase 1 AI851983 2.3 ± 0.2 2.3 ± 0.1 2.6 ± 0.3 START domain-containing 3 X82457 1.5 ± 0.1 1.4 ± 0.03 1.5 ± 0.01 CD68 antigen X68273 4.6 ± 0.6 4.2 ± 0.6 5.0 ± 0.7 RIKEN cDNA E030027H19 AW211760 2.7 ± 0.3 2.7 ± 0.2 2.9 ± 0.1 cDNA sequence BC004044 AI461767 3.1 ± 0.2 3.4 ± 0.1 3.8 ± 0.5 E74-like factor 3 AF016294 5.1 ± 0.8 5.9 ± 0.5 6.5 ± 0.5 Glutathione S-transferase AI843119 5.0 ± 1.1 4.6 ± 0.6 4.1 ± 0.7 omega 1 Interferon-stimulated protein 20 AW122677 4.2 ± 0.1 4.3 ± 0.7 3.4 ± 0.4 Clusterin D14077 3.6 ± 0.7 3.9 ± 0.9 3.4 ± 0.4
Galectin 3 X16834 7.4 ± 1.3 8.7 ± 0.7 6.9 ± 0.4 Small proline-rich protein 2A b AJ005559 51.1 ± 4.0 78.3 ± 15.7 44.2 ± 5.2 Complement component 3 b K02782 14.8 ± 1.8 18.8 ± 1.0 14.8 ± 0.8 Small proline-rich protein 2C AJ005561 220.3± 31.0 340.5 ± 37.1 214.1 ± 41.1 Small proline-rich protein 2G AJ005565 9.4 ± 0.9 11.0 ± 0.3 9.6 ± 0.6 Prominin AF039663 3.5 ± 0.5 3.6 ± 0.6 3.4 ± 0.3 Lactotransferrin b J03298 88.7 ± 18.4 99.2 ± 13.9 76.9 ± 21.8 Carbonic anhydrase 2 M25944 7.9 ± 0.5 8.2 ± 0.9 7.3 ± 0.4 Complement component U47810 36.5 ± 4.4 38.4 ± 5.6 32.9 ± 4.2 factor I Mannosidase 2alphaB1 U87240 2.0 ± 0.2 2.0 ± 0.1 1.9 ± 0.1 Small proline-rich protein 2B AJ005560 32.9 ± 3.7 39.2 ± 1.9 30.7 ± 5.0 Small proline-rich protein 2A b AJ005559 269.8 ± 23.7 329.1 ± 42.9 59.1 ± 40.8 RIKEN cDNA 5830413E08 AI849939 3.3 ± 0.4 3.3 ± 0.5 3.0 ± 0.3 RIKEN cDNA 1110029F20 AW125508 4.1 ± 0.1 4.1 ± 0.4 3.7 ± 0.1 Annexin A3 AJ001633 2.7 ± 0.5 4.2 ± 0.7 3.2 ± 0.6 Peptidase 4 U51014 2.0 ± 0.1 2.9 ± 0.3 2.3 ± 0.2 Laminin gamma 2 U43327 6.3 ± 1.3 17.3 ± 6.8 10.2 ± 1.0 Ubiquitin-like 3 AW120725 1.5 ± 0.1 1.8 ± 0.1 1.7 ± 0.03 Urate oxidase M27695 23.8 ± 9.5 143.9 ± 62.9 43.8 ±17.7 Amiloride binding protein 1 AI197481 3.5 ± 1.0 10.1 ± 0.8 6.0 ± 1.2 Keratin complex 1-19 AU040563 4.5 ± 1.0 7.2 ± 1.0 5.6 ± 0.4 Activated leukocyte cell L25274 3.6 ± 0.8 5.1 ± 0.9 4.4 ± 0.5 adhesion molecule CCAAT/enhancer binding M61007 2.3 ± 0.1 2.8 ± 0.3 2.6 ± 0.1 protein β Peptidyl arginine deiminase, AB013848 8.6 ± 0.7 15.8 ± 3.1 12.0 ± 1.7 type I Enolase 1 α AI841389 2.5 ± 0.3 3.2 ± 0.5 3.0 ± 0.3 p53 apoptosis effector related AI854029 2.9 ± 0.3 4.1 ± 0.8 3.7 ± 0.5 to Pmp22 β-Glucuronidase M19279 1.9 ± 0.1 2.3 ± 0.2 2.2 ± 0.1 Leucine-rich AW230891 9.3 ± 1.1 17.6 ± 4.1 14.5 ± 2.6 α-2-glycoprotein Quiescin Q6 AW123556 3.7 ± 0.2 5.5 ± 1.2 4.8 ± 0.7 GADD45a U00937 1.9 ± 0.2 2.6 ± 0.3 2.3 ± 0.1 Alkaline phosphatase 2 J02980 9.2 ± 0.4 22.6 ± 6.2 15.8 ± 2.0 Immediate early response 3 X67644 5.5 ± 0.8 10.8 ± 2.2 8.9 ± 2.0 Progressive ankylosis AW049351 2.2 ± 0.1 2.9 ± 0.4 2.8 ± 0.4 RAS p21 protein activator 4 AA163960 6.8 ± 0.9 14.2 ± 2.5 12.1 ± 1.7 Tumor-associated calcium M76124 2.1 ± 0.2 2.7 ± 0.3 2.6 ± 0.2 signal transducer 1 Hydroxysteroid (17-beta) AA822174 1.9 ± 0.1 2.3 ± 0.3 2.4 ± 0.1 dehydrogenase 11 Figure 3C . b Genes mentioned in the text.
Platelet-activating factor U57746 1.9 ± 0.1 2.2 ± 0.2 2.3 ± 0.1 acetylhydrolase 1ba1 Branched chain U42443 2.4 ± 0.2 3.4 ± 0.2 3.4 ± 0.01 aminotransferase 1 RIKEN cDNA 2400004E04 AI846720 1.7 ± 0.1 2.4 ± 0.2 2.3 ± 0.2 Myeloblastosis oncogene M12848 2.8 ± 0.4 5.6 ± 1.1 5.0 ± 0.2 K + conductance calcium-AF042487 3.1 ± 0.2 4.2 ± 0.6 3.5 ± 0.8 activated channel N4 ATPase 6v1b2 AI843029 1.7 ± 0.1 1.8 ± 0.1 1.8 ± 0.1 Cystic fibrosis transmembrane M60493 3.4 ± 0.5 4.5 ± 0.8 3.9 ± 0.3 regulator RIKEN cDNA 1110008P14 AI839839 4.3 ± 0.4 6.0 ± 1.0 5.1 ± 0.2 Fused toes Z67963 2.6 ± 0.2 3.2 ± 0.3 2.8 ± 0.1 Solute carrier family 39a8 AW124340 3.5 ± 0.5 4.5 ± 0.7 3.8 ± 0.3 Cytochrome b-561 AI846517 2.2 ± 0.2 2.5 ± 0.2 2.3 ± 0.2 Secreted phosphoprotein 1 X13986 30.2 ± 3.3 47.4 ± 7.4 31.1 ± 2.7 Ion transport regulator Fxyd3 X93038 5.3 ± 0.4 6.8 ± 1.1 5.5 ± 0.6 Janus kinase 3 L40172 2.1 ± 0.2 2.5 ± 0.2 2.2 ± 0.2 Cytochrome b-245alpha AW046124 2.9 ± 0.4 3.6 ± 0.4 2.9 ± 0.2 RIKEN cDNA A430096B05 AI465965 6.3 ± 1.0 8.6 ± 0.03 6.3 ± 0.6 Small proline-rich protein 2J AJ005568 8.6 ± 2.1 13.8 ± 3.2 8.5 ± 0.7 Cathepsin B M65270 2.2 ± 0.1 2.6 ± 0.2 2.2 ± 0.1 RIKEN cDNA 1600025H15 AI842734 2.2 ± 0.1 2.7 ± 0.3 2.2 ± 0.2 c-fos oncogene b V00727 3.2 ± 0.4 4.7 ± 0.9 3.7 ± 0.8 Guanine nucleotide binding AI843937 1.6 ± 0.1 1.8 ± 0.1 1.6 ± 0.03 protein γ5 Serine palmitoyltransferase U27455 1.6 ± 0.1 2.0 ± 0.2 1.7 ± 0.1 lc2 Cystatin B U59807 1.5 ± 0.1 1.7 ± 0.1 1.5 ± 0.02 Villin 2 X60671 1.9 ± 0.2 2.4 ± 0.3 1.9 ± 01 RIKEN cDNA 0610010O12 AI849011 1.9 ± 0.1 2.5 ± 0.3 1.9 ± 0.03 Matrix metalloproteinase 7 L36244 47.8 ± 18.6 208.6 ± 83.3 48.2 ± 11.9 RIKEN cDNA 4930422J18 AV376312 2.0 ± 0.3 2.9 ± 0.3 2.0 ± 0.2 RIKEN cDNA 1700017B05 AW049360 1.6 ± 0.1 2.0 ± 0.1 1.6 ± 0.1 Galactosidase beta 1 M57734 1.8 ± 0.1 2.0 ± 0.1 1.7 ± 0.1 Cathepsin C U74683 2.6 ± 0.1 3.3 ± 0.2 2.3 ± 0.3 Interferon-stimulated X56602 3.6 ± 0.6 2.0 ± 0.2 3.8 ± 0.7 protein 15 MAP kinase-interacting Y11092 1.8 ± 0.1 1.4 ± 0.1 1.9 ± 0.1 kinase 2 Glutathione S-transferase X98056 3.5 ± 0.4 2.9 ± 0.4 3.6 ± 0.2 theta 2 Homeobox B6 M18401 1.5 ± 0.02 1.5 ± 0.1 1.6 ± 0.03 Procollagen VIalpha 3
